Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015

Timothy J. Price; Subotheni Thavaneswaran; Matthew Burge; Eva Segelov; Daniel G. Haller; Cornelis Ja Punt; Dirk Arnold; Christos S. Karapetis; Niall C. Tebbutt; Nick Pavlakis; Peter Gibbs; Jeremy D. Shapiro

doi:https://doi.org/10.1586/14737140.2016.1170594

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015

Timothy J. Price, Subotheni Thavaneswaran, Matthew Burge, Eva Segelov, Daniel G. Haller, Cornelis Ja Punt, Dirk Arnold, Christos S. Karapetis, Niall C. Tebbutt, Nick Pavlakis, Peter Gibbs, Jeremy D. Shapiro

Oncology (AMC)

Research output: Contribution to journal › Review article › Academic › peer-review

6 Citations (Scopus)

Abstract

The treatment of metastatic CRC (mCRC) has evolved over the last 20 years, from fluoropyrimidines alone to combination chemotherapy and new biologic agents. Median overall survival is now over 24 months for RAS mutated (MT) patients and over 30 months for RAS wild-type (WT) patients. However, there are subgroups of patients with BRAF V600E MT CRC who have a significantly poorer outlook. Newer treatment options are also being explored in select subgroups of patients (anti-HER 2 in HER2 positive mCRC and immunotherapy in patients with defective mismatch repair (dMMR)). The best use of these systemic treatment options, as well as surgery in well-selected patients requires careful consideration of predictive biomarkers and importantly, the optimal sequence in which therapies should be given to derive maximal benefit. A group of colorectal subspecialty medical oncologists from Australia, USA, The Netherlands and Germany met during ECCO 2015 in Vienna to review current practice

Original language	English
Pages (from-to)	557-571
Journal	Expert Review of Anticancer Therapy
Volume	16
Issue number	5
DOIs	https://doi.org/10.1586/14737140.2016.1170594
Publication status	Published - 2016

Access to Document

https://doi.org/10.1586/14737140.2016.1170594

Cite this

Price, T. J., Thavaneswaran, S., Burge, M., Segelov, E., Haller, D. G., Punt, C. J., Arnold, D., Karapetis, C. S., Tebbutt, N. C., Pavlakis, N., Gibbs, P., & Shapiro, J. D. (2016). Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. Expert Review of Anticancer Therapy, 16(5), 557-571. https://doi.org/10.1586/14737140.2016.1170594

@article{c10a79e1fbf141ff90e8bd915eced581,

title = "Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015",

abstract = "The treatment of metastatic CRC (mCRC) has evolved over the last 20 years, from fluoropyrimidines alone to combination chemotherapy and new biologic agents. Median overall survival is now over 24 months for RAS mutated (MT) patients and over 30 months for RAS wild-type (WT) patients. However, there are subgroups of patients with BRAF V600E MT CRC who have a significantly poorer outlook. Newer treatment options are also being explored in select subgroups of patients (anti-HER 2 in HER2 positive mCRC and immunotherapy in patients with defective mismatch repair (dMMR)). The best use of these systemic treatment options, as well as surgery in well-selected patients requires careful consideration of predictive biomarkers and importantly, the optimal sequence in which therapies should be given to derive maximal benefit. A group of colorectal subspecialty medical oncologists from Australia, USA, The Netherlands and Germany met during ECCO 2015 in Vienna to review current practice",

author = "Price, {Timothy J.} and Subotheni Thavaneswaran and Matthew Burge and Eva Segelov and Haller, {Daniel G.} and Punt, {Cornelis Ja} and Dirk Arnold and Karapetis, {Christos S.} and Tebbutt, {Niall C.} and Nick Pavlakis and Peter Gibbs and Shapiro, {Jeremy D.}",

year = "2016",

doi = "https://doi.org/10.1586/14737140.2016.1170594",

language = "English",

volume = "16",

pages = "557--571",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Expert Reviews Ltd.",

number = "5",

}

Price, TJ, Thavaneswaran, S, Burge, M, Segelov, E, Haller, DG, Punt, CJ, Arnold, D, Karapetis, CS, Tebbutt, NC, Pavlakis, N, Gibbs, P & Shapiro, JD 2016, 'Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015', Expert Review of Anticancer Therapy, vol. 16, no. 5, pp. 557-571. https://doi.org/10.1586/14737140.2016.1170594

TY - JOUR

T1 - Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015

AU - Price, Timothy J.

AU - Thavaneswaran, Subotheni

AU - Burge, Matthew

AU - Segelov, Eva

AU - Haller, Daniel G.

AU - Punt, Cornelis Ja

AU - Arnold, Dirk

AU - Karapetis, Christos S.

AU - Tebbutt, Niall C.

AU - Pavlakis, Nick

AU - Gibbs, Peter

AU - Shapiro, Jeremy D.

PY - 2016

Y1 - 2016

N2 - The treatment of metastatic CRC (mCRC) has evolved over the last 20 years, from fluoropyrimidines alone to combination chemotherapy and new biologic agents. Median overall survival is now over 24 months for RAS mutated (MT) patients and over 30 months for RAS wild-type (WT) patients. However, there are subgroups of patients with BRAF V600E MT CRC who have a significantly poorer outlook. Newer treatment options are also being explored in select subgroups of patients (anti-HER 2 in HER2 positive mCRC and immunotherapy in patients with defective mismatch repair (dMMR)). The best use of these systemic treatment options, as well as surgery in well-selected patients requires careful consideration of predictive biomarkers and importantly, the optimal sequence in which therapies should be given to derive maximal benefit. A group of colorectal subspecialty medical oncologists from Australia, USA, The Netherlands and Germany met during ECCO 2015 in Vienna to review current practice

AB - The treatment of metastatic CRC (mCRC) has evolved over the last 20 years, from fluoropyrimidines alone to combination chemotherapy and new biologic agents. Median overall survival is now over 24 months for RAS mutated (MT) patients and over 30 months for RAS wild-type (WT) patients. However, there are subgroups of patients with BRAF V600E MT CRC who have a significantly poorer outlook. Newer treatment options are also being explored in select subgroups of patients (anti-HER 2 in HER2 positive mCRC and immunotherapy in patients with defective mismatch repair (dMMR)). The best use of these systemic treatment options, as well as surgery in well-selected patients requires careful consideration of predictive biomarkers and importantly, the optimal sequence in which therapies should be given to derive maximal benefit. A group of colorectal subspecialty medical oncologists from Australia, USA, The Netherlands and Germany met during ECCO 2015 in Vienna to review current practice

U2 - https://doi.org/10.1586/14737140.2016.1170594

DO - https://doi.org/10.1586/14737140.2016.1170594

M3 - Review article

C2 - 27010906

SN - 1473-7140

VL - 16

SP - 557

EP - 571

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

IS - 5

ER -